Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Analyst Comments: Corrections Corp, Alnylam Pharma, Ryland, Eurand Pharma, HCP
Aug 11, 2008 12:23 PM
- Analyst Comments: FedEx, Patterson-UTI, COPEL, Semtech, Eurand
Jun 20, 2008 10:29 AM
- Analyst Comments: Cyclacel, Wonder Auto, NeurogesX, Kodiak Oil & Gas, Nordstrom, AmBev, Eurand, Sony, J.C. Penney, Barclays
May 16, 2008 04:00 PM
- Biotech to Outperform in Down Market
Apr 21, 2008 06:20 PM
- Analyst Comments: Colgate, Stoneridge, U.S. Auto Parts, Eurand, Coca-Cola, Pacific Rim Telecom
Mar 10, 2008 01:26 PM
- Bullish on Eurand Biopharm
Jan 11, 2008 10:26 AM
- Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Nov 26, 2008 08:31 AM
- Eurand Appoints Dr. Ruth Thieroff-Ekerdt as Chief Medical Officer
Nov 20, 2008 11:01 AM
- Eurand to Present At Lazard Capital Markets 5th Annual Healthcare Conference
Nov 11, 2008 02:12 PM
- Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. And GlaxoSmithKline Inc.
Nov 11, 2008 07:18 AM
- Eurand Reports Recent Developments and Third Quarter and Year-to-Date 2008 Financial Results
Nov 07, 2008 07:03 AM
- Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
Oct 21, 2008 09:04 AM
- Eurand Announces Conference Call On Third Quarter 2008 Financial Results
Oct 09, 2008 12:31 PM
- Eurand Provides Update On EUR-1008 (ZENTASE)
Sep 30, 2008 09:32 AM
- Eurand to Present At Thomas Weisel Partners Healthcare Conference 2008
Aug 26, 2008 10:38 AM
- Zacks Analyst Blog Highlights: Comerica Inc., Advance Auto Parts, Inc., Eurand N.V., Cephalon Inc. And GlaxoSmithKline Plc.
Aug 12, 2008 08:06 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
EURX
|
Compare to S&P
|
| YTD |
-51.52 %
|
-0.01 %
|
| 4 Weeks |
-16.28 %
|
-8.40 %
|
| 12 Weeks |
-56.08 %
|
-37.85 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 60.00 %
|
|
EPS Growth in Last Year: -50.00 %
|
|
Sales Growth in Last Quarter: -28.01 %
|
|
Sales Growth in Last Quarter: 48.87 %
|
|
|
